학술논문
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Document Type
article
Author
José Luis Piñana; Lourdes Vazquez; Marisa Calabuig; Lucia López-Corral; Gabriel Martin-Martin; Lucia Villalon; Gabriela Sanz-Linares; Venancio Conesa-Garcia; Andrés Sanchez-Salinas; Beatriz Gago; Ana Facal; Irene Risco-Gálvez; María T. Olave; Ildefonso Espigado; Javier Lopez-Jimenez; José Ángel Hernández-Rivas; Alejandro Avendaño-Pita; Ignacio Arroyo; Elena Ferrer; Irene García-Cadenas; Clara González-Santillana; Alicia Roldán-Pérez; Blanca Ferrer; Manuel Guerreiro; María Suarez-Lledó; Angela Camara; Diana Campos-Beltrán; David Navarro; Ángel Cedillo; Anna Sureda; Carlos Solano; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC); Rodrigo Martino
Source
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-14 (2023)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 to July 2022 by the Spanish Transplant and Cell Therapy group, was used to analyze the relationship of antibody response over time after full vaccination (at 3–6 weeks, 3, 6 and 12 months) (2 doses) and of booster doses with breakthrough SARS-CoV-2 infection in 1551 patients with hematological disorders. At a median follow-up of 388 days after complete immunization, 266 out of 1551 (17%) developed breakthrough SARS-CoV-2 infection at median of 86 days (range 7–391) after full vaccination. The cumulative incidence was 18% [95% confidence interval (C.I.), 16–20%]. Multivariate analysis identified higher incidence in chronic lymphocytic leukemia patients (29%) and with the use of corticosteroids (24.5%), whereas female sex (15.5%) and more than 1 year after last therapy (14%) were associated with a lower incidence (p